Company Overview and News


Add COV
to your dashboard

Headline News

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

2017-10-13 prnewswire
NEW YORK, Oct. 13, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the third quarter 2017 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. (19-0)

Covalon Technologies Ltd. Announces Major Milestone: FDA Clearance For MediClear PreOp

2017-09-21 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announced today it has received United States Food and Drug Administration (“FDA”) clearance to legally market and sell MediClear™ PreOp in the US to hospitals, clinics and directly to patients, without the need for a prescription. (15-0)

Covalon Technologies Wins FDA Clearance for MediClear PreOp

2017-09-21 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announced today it has received United States Food and Drug Administration (“FDA”) clearance to legally market and sell MediClear™ PreOp in the US to hospitals, clinics and directly to patients, without the need for a prescription. (15-0)

Covalon Technologies Announces Conference Call To Discuss Q3 Financial Results

2017-08-18 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to be held Tuesday August 22, 2017 at 9:00 a.m. EDT, to discuss the third quarter ended June 30, 2017, financial results. The Company intends to release its Q3 financial results on Monday August 21, 2017.

Covalon Technologies Ltd. Announces First Time Attendance At The 32nd Annual Conference

2017-07-06 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be exhibiting for the first time at the 32nd Annual Oley Consumer/Clinician Conference taking place at the Hyatt Regency in Old Greenwich, CT from July 5-8, 2017.

Global Hydrophilic Coatings Market is Expected to Reach US$ 1,026.6 Mn in 2025: Transparency Market Research

2017-06-08 prnewswire
Transparency Market Research has published a new report titled "Hydrophilic Coatings (Polymers, Metals & Metal Alloys and Glass & Other Ceramics) Market for Automotive, Aerospace, Medical Devices (Cardiovascular, Urology, Neurology, General Surgery and Others) Optical and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 - 2025." According to the report, the global market for hydrophilic coatings was valued at US$ 481.

Covalon Technologies Ltd. Releases Second Quarter Financial Results

2017-05-30 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, announced today its second quarter financial results, which included revenue of $6,005,336 and net income of $473,524 or $0.02 per share for the three months ended March 31, 2017 and revenue of $11,571,005 and net income of $1,011,188 or $0.05 per share for the six months ended March 31, 2017.

Covalon Technologies Ltd. Brings Aboard Advisors to Hunt for Strategic Acquisitions

2017-05-16 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has engaged MPA Morrison Park Advisors Inc. (“MPA”) as a financial advisor to help the Company accelerate its growth and expansion by pursuing strategic acquisitions and enhance the Company’s profile in the capital markets and investment community.

Covalon Technologies Ltd. Launches Centaur Low Particulate, Lubricious Coating For Medical Devices

2017-04-27 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the launch of its new, Centaur™ low particulate, lubricious coating designed to improve the safety and functionality of intravascular medical devices such as catheters, guidewires and delivery sheaths where the presence of unwanted particulate can cause significant patient complications.

Research Reports Initiated on Healthcare Stocks Sirona Biochem, MedMira, Covalon Technologies, and Revive Therapeutics

2017-04-10 accesswire
LONDON, UK / ACCESSWIRE / April 10, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Sirona Biochem, MedMira, Covalon Technologies, and Revive Therapeutics.

Covalon Technologies Ltd. Announces Issuance Of Stock Options

2017-02-09 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the issuance of an aggregate of 265,000 stock options to employees and consultants of the Company. The stock options will vest over three years and will be exercisable for a period of five years at an exercise price of $2.20 per stock option.

BRIEF-Covalon posts record first quarter financial results

2017-01-30 reuters
* Covalon Technologies Ltd qtrly revenue of $5.6 million $2.4 million Source text for Eikon: Further company coverage:

Implantable Biomaterials Market Material, Application Analysis & Trends 2016-2025: $150+ Billion Growth Opportunities/Investment Opportunities - Research and Markets

2017-01-19 prnewswire
The Global Implantable Biomaterials Market is poised to grow at a CAGR of around 7.5% over the next decade to reach approximately $165.31 billion by 2025.

Covalon Technologies Ltd. CEO Provides Update On Anticipated Fiscal 2017 Financial Growth

2017-01-03 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, announced today an update by the Company’s Chief Executive Officer on Covalon’s anticipated financial growth for fiscal 2017.

Covalon Technologies Ltd. CEO Provides Update On Anticipated Fiscal 2017 Financial Growth

2017-01-03 devicespace
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, announced today an update by the Company’s Chief Executive Officer on Covalon’s anticipated financial growth for fiscal 2017.